SynthesisDrug design, development and therapy2018

Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.

Jiang-Dong Sui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.